With improved biobanking of rare cancer tissue enabling more in-depth tumour profiling, as well as generation of clinically relevant rare cancer preclinical models, treatment strategies for patients with rare cancer will rapidly advance. The future successes of rare cancer research, with alternative approaches for diagnosing, researching and conducting clinical trials, will ultimately benefit patients with all types of cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Journal of Experimental & Clinical Cancer Research Open Access 04 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gatta, G. et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 18, 1022–1039 (2017).
Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744–750 (2019).
Puca, L. et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat. Commun. 9, 2404 (2018).
Phan, N. et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun. Biol. 2, 78 (2019).
Ray-Coquard, I., Pujade-Lauraine, E. & Ledermann, J. A. New clinical research strategies for rare gynecologic malignancies. Curr. Opin. Obstet. Gynecol. 27, 53–57 (2015).
Nunn, J. S. et al. in Textbook of Uncommon Cancers 5th edn (eds Raghavan, D. et al.) 12–18 (Wiley, 2017).
Acknowledgements
This work was supported by fellowships from the Stafford Fox Medical Research Foundation (C.L.S. and H.E.B.); Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research to C.L.S.); the Victorian Cancer Agency (Clinical Fellowships CRF10-20 and CRF16014 to C.L.S.). This work was made possible through the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council Independent Medical Research Institutes Infrastructure Support Scheme.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
CART-Wheel.org: https://www.cart-wheel.org/
International Rare Cancers Initiative: http://www.irci.info/
Supplementary Information
Rights and permissions
About this article
Cite this article
Barker, H.E., Scott, C.L. Preclinical rare cancer research to inform clinical trial design. Nat Rev Cancer 19, 481–482 (2019). https://doi.org/10.1038/s41568-019-0172-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-019-0172-2
This article is cited by
-
Challenges and opportunities in rare cancer research in China
Science China Life Sciences (2024)
-
Rare tumors: a blue ocean of investigation
Frontiers of Medicine (2023)
-
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Journal of Experimental & Clinical Cancer Research (2023)
